We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Early Detection of Osteoarthritis May Provide Possibility for a Cure

By LabMedica International staff writers
Posted on 23 Jun 2009
Researchers are investigating potential biomarkers in dogs for early diagnosis of osteoarthritis, which could help identify patients at increased risk of developing the degenerative joint disease.

Osteoarthritis is typically diagnosed in the late and irreversible stages, when treatment can only be expected to decrease pain and slow progression of disease. More...
Because osteoarthritis is a widespread problem in dogs, horses, and humans, physicians and veterinarians need a precise way to diagnose the disease early and accurately.

"By developing methods for earlier diagnosis of osteoarthritis, prevention or even curative treatment strategies to manage the disease become more realistic,” said Dr. James Cook, professor of veterinary medicine and surgery, and professor of orthopedic surgery at the University of Missouri (MU; Columbia, USA). "Biomarkers could detect the disease before pain and swelling occurs, and owners could take preventative measures, such as modifying activities or diet, helping their pets lose weight and strengthen their joints, to reduce the likelihood of their dogs developing osteoarthritis.”

In the study, researchers examined potential biomarkers in synovial fluid. Synovial fluid, which lubricates the joints, is known to have sensitive and rapid responses to joint injury. Taking samples from dogs, researchers discovered that synovial fluid quantity and quality were altered in injured stifle joints (the joint in the hind limbs of dogs that is the equivalent joint to the human knee).

"At the MU Comparative Orthopedic Laboratory, we are particularly interested in identification and validation of biomarkers that can detect early stages of osteoarthritis to provide accurate diagnostic and prognostic information prior to the onset of clinical disease for people and for pets,” Dr. Cook said. "Our team, led by Drs. Kuroki, Stoker, and Garner, is making tremendous progress in developing simple tests on blood, urine, and synovial fluid that show great promise for helping us diagnose impending osteoarthritis before it is too late to help the patient in the most effective manner.”

Osteoarthritis causes degradation of articular cartilage, leading to pain, inflammation, and loss of motion in the joint. Veterinarians predict that 20% of middle-aged dogs and 90% of older dogs have osteoarthritis in one or more joints and the percentages are even higher for the human population.

Related Links:

University of Missouri-Columbia


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.